Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Stable Gastric Pentadecapeptide BPC 157 Can Improve the Healing Course of Spinal Cord Injury and Lead to Functional Recovery in Rats
The $50 lost peptide is cheaper than treating an infection
Today over 100 peptide medications are approved, including semaglutide better known as Ozempic and Wegovy
Category 1 Bulk substance the FDA considers eligible for use in compounding pending final rulemaking Generally permitted Category 2 Bulk substance the FDA has significant safety, identity, or quality concerns about Not permitted during review Category 3 Substance requiring further evaluation Case-by-case Critically, Category 1 status is not FDA approval
The durability of the glucagon-mediated metabolic changes after drug washout is an open research question that Phase 3 extension studies are expected to address
BPC-157 is a synthetic pentadecapeptide derived from a protective gastric protein
